Nuvation Bio Inc. (NUVB)

3,1000 +0,1100 (+3,68%) Börsenschluss: 04:00PM EDT

Nuvation Bio Inc.

1500 Broadway
Suite 1401
New York, NY 10036
United States
332 208 6102
https://www.nuvationbio.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 159

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. David T. Hung M.D.	Founder, President, CEO & Director	1M	N/A	1958
Dr. Gary Hattersley Ph.D.	Chief Scientific Officer	694,56k	N/A	1967
Dr. David Liu M.D., Ph.D.	Chief Medical Officer	677,15k	N/A	1970
Mr. Moses Makunje CPA	VP of Finance and Principal Accounting & Financial Officer	N/A	N/A	1979
Ms. Stacy Markel	Chief People Officer	N/A	N/A	1965
Dr. David C. Hanley Ph.D.	Chief Technical Operations Officer	586,04k	N/A	1970
Ms. Kerry A. Wentworth	Chief Regulatory Officer	N/A	N/A	1973
Ms. Colleen Sjogren	Chief Commercial Officer	N/A	N/A	1970
Dr. Junyuan Wang Ph.D.	CEO & Co-Founder of AnHeart Therapeutics and Director	N/A	N/A	1973

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

Corporate Governance

Nuvation Bio Inc.s ISS Governance QualityScore, Stand 1. Juni 2024, lautet 10. Die grundlegenden Scores sind Audit: 8, Vorstand: 8, Shareholderrechte: 10, Kompensation: 10.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.